These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25952485)

  • 21. Mammography surveillance and mortality in older breast cancer survivors.
    Lash TL; Fox MP; Buist DS; Wei F; Field TS; Frost FJ; Geiger AM; Quinn VP; Yood MU; Silliman RA
    J Clin Oncol; 2007 Jul; 25(21):3001-6. PubMed ID: 17548838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance testing among survivors of early-stage breast cancer.
    Keating NL; Landrum MB; Guadagnoli E; Winer EP; Ayanian JZ
    J Clin Oncol; 2007 Mar; 25(9):1074-81. PubMed ID: 17369571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Big 3: An Updated Overview of Colorectal, Breast, and Prostate Cancers.
    Gordon J; Fischer-Cartlidge E; Barton-Burke M
    Nurs Clin North Am; 2017 Mar; 52(1):27-52. PubMed ID: 28189165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Area-level variations in cancer care and outcomes.
    Keating NL; Landrum MB; Lamont EB; Bozeman SR; McNeil BJ
    Med Care; 2012 May; 50(5):366-73. PubMed ID: 22437623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer.
    Ramsey SD; Berry K; Etzioni R
    Am J Gastroenterol; 2002 Feb; 97(2):440-5. PubMed ID: 11866285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Worry about breast cancer recurrence: a population-based analysis.
    Tewari A; Chagpar AB
    Am Surg; 2014 Jul; 80(7):640-5. PubMed ID: 24987893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective surveillance model for rehabilitation for women with breast cancer.
    Stout NL; Binkley JM; Schmitz KH; Andrews K; Hayes SC; Campbell KL; McNeely ML; Soballe PW; Berger AM; Cheville AL; Fabian C; Gerber LH; Harris SR; Johansson K; Pusic AL; Prosnitz RG; Smith RA
    Cancer; 2012 Apr; 118(8 Suppl):2191-200. PubMed ID: 22488693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer.
    Shih YC; Elting LS; Pavluck AL; Stewart A; Halpern MT
    Cancer Invest; 2010 Jan; 28(1):46-53. PubMed ID: 19995227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of guidance on recurrence risk management for general practitioners in breast cancer, colorectal cancer and melanoma guidelines.
    Spronk I; Korevaar JC; Burgers JS; Albreht T; Schellevis FG
    Fam Pract; 2017 Apr; 34(2):154-160. PubMed ID: 28207044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of guideline recommended follow-up care in cancer survivors: routine or diagnostic indications?
    Cooper GS; Johnson CC; Lamerato L; Poisson LM; Schultz L; Simpkins J; Wells K; Yood MU; Chase G; Nathanson SD; Lafata JE
    Med Care; 2006 Jun; 44(6):590-4. PubMed ID: 16708008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.
    Khan NF; Mant D; Carpenter L; Forman D; Rose PW
    Br J Cancer; 2011 Nov; 105 Suppl 1(Suppl 1):S29-37. PubMed ID: 22048030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
    Armstrong A; Otvos B; Singh S; Debernardo R
    Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer.
    Pfister DG; Benson AB; Somerfield MR
    N Engl J Med; 2004 Jun; 350(23):2375-82. PubMed ID: 15175439
    [No Abstract]   [Full Text] [Related]  

  • 35. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis.
    Edelman MJ; Meyers FJ; Siegel D
    J Gen Intern Med; 1997 May; 12(5):318-31. PubMed ID: 9159703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm.
    Jochelson M; Hayes DF; Ganz PA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colorectal cancer survivors need better follow-up care.
    Sinha G
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25313227
    [No Abstract]   [Full Text] [Related]  

  • 40. NCCN Practice Guidelines for Prostate Cancer.
    Bahnson RR; Hanks GE; Huben RP; Kantoff P; Kozlowski JM; Kuettel M; Lange PH; Logothetis C; Pow-Sang JM; Roach M; Sandler H; Scardino PT; Taylor RJ; Urban DA; Walsh PC; Wilson TG;
    Oncology (Williston Park); 2000 Nov; 14(11A):111-9. PubMed ID: 11195405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.